Patient and transplantation characteristics
| Characteristic . | ABX-CBL dose group (mg/kg) . | All patients . | ||||
|---|---|---|---|---|---|---|
| 0.01 . | 0.1 . | 0.15 . | 0.2 . | 0.3 . | ||
| No. patients | 9 | 7 | 5 | 35 | 3 | 59 |
| Median age, y (range) | 43 | 32 | 31 | 37 | 27 | 36 |
| (12-49) | (5-46) | (14-53) | (1-59) | (1-43) | (1-59) | |
| Primary diagnoses (no. patients) | ||||||
| Acute leukemia | 4 | 2 | 2 | 13 | 2 | 23 |
| Chronic leukemia | 3 | 3 | 1 | 8 | 0 | 15 |
| Lymphoma | 1 | 0 | 1 | 2 | 0 | 4 |
| Other | 1 | 2 | 1 | 12 | 1 | 17 |
| Conditioning regimen (no. patients) | ||||||
| Contained TBI | 6 | 4 | 5 | 20 | 2 | 37 |
| No TBI | 3 | 3 | 0 | 15 | 1 | 22 |
| GVHD prophylaxis (no. patients)* | ||||||
| CYA + MTX | 6 | 5 | 3 | 16 | 2 | 32 |
| FK506+ | 2 | 1 | 2 | 4 | 0 | 9 |
| CYA+ | 0 | 0 | 0 | 10 | 1 | 11 |
| MTX+ | 0 | 1 | 0 | 4 | 0 | 5 |
| Other | 1 | 0 | 0 | 1 | 0 | 2 |
| Source of stem cells (no. patients) | ||||||
| Marrow | 7 | 7 | 3 | 31 | 3 | 51 |
| PBSC | 2 | 0 | 2 | 2 | 0 | 6 |
| Cord blood | 0 | 0 | 0 | 2 | 0 | 2 |
| Donor (no. patients)† | ||||||
| Related: HLA = | 5 | 1 | 4 | 14 | 2 | 26 |
| HLA ≠ | 1 | 1 | 0 | 2 | 0 | 4 |
| Unrelated: HLA = | 2 | 4 | 1 | 12 | 1 | 20 |
| HLA ≠ | 1 | 1 | 0 | 7 | 0 | 9 |
| IBMTR index (no. patients) | ||||||
| B | 2 | 2 | 1 | 7 | 2 | 14 |
| C | 3 | 2 | 2 | 14 | 1 | 22 |
| D | 4 | 3 | 2 | 14 | 0 | 23 |
| Characteristic . | ABX-CBL dose group (mg/kg) . | All patients . | ||||
|---|---|---|---|---|---|---|
| 0.01 . | 0.1 . | 0.15 . | 0.2 . | 0.3 . | ||
| No. patients | 9 | 7 | 5 | 35 | 3 | 59 |
| Median age, y (range) | 43 | 32 | 31 | 37 | 27 | 36 |
| (12-49) | (5-46) | (14-53) | (1-59) | (1-43) | (1-59) | |
| Primary diagnoses (no. patients) | ||||||
| Acute leukemia | 4 | 2 | 2 | 13 | 2 | 23 |
| Chronic leukemia | 3 | 3 | 1 | 8 | 0 | 15 |
| Lymphoma | 1 | 0 | 1 | 2 | 0 | 4 |
| Other | 1 | 2 | 1 | 12 | 1 | 17 |
| Conditioning regimen (no. patients) | ||||||
| Contained TBI | 6 | 4 | 5 | 20 | 2 | 37 |
| No TBI | 3 | 3 | 0 | 15 | 1 | 22 |
| GVHD prophylaxis (no. patients)* | ||||||
| CYA + MTX | 6 | 5 | 3 | 16 | 2 | 32 |
| FK506+ | 2 | 1 | 2 | 4 | 0 | 9 |
| CYA+ | 0 | 0 | 0 | 10 | 1 | 11 |
| MTX+ | 0 | 1 | 0 | 4 | 0 | 5 |
| Other | 1 | 0 | 0 | 1 | 0 | 2 |
| Source of stem cells (no. patients) | ||||||
| Marrow | 7 | 7 | 3 | 31 | 3 | 51 |
| PBSC | 2 | 0 | 2 | 2 | 0 | 6 |
| Cord blood | 0 | 0 | 0 | 2 | 0 | 2 |
| Donor (no. patients)† | ||||||
| Related: HLA = | 5 | 1 | 4 | 14 | 2 | 26 |
| HLA ≠ | 1 | 1 | 0 | 2 | 0 | 4 |
| Unrelated: HLA = | 2 | 4 | 1 | 12 | 1 | 20 |
| HLA ≠ | 1 | 1 | 0 | 7 | 0 | 9 |
| IBMTR index (no. patients) | ||||||
| B | 2 | 2 | 1 | 7 | 2 | 14 |
| C | 3 | 2 | 2 | 14 | 1 | 22 |
| D | 4 | 3 | 2 | 14 | 0 | 23 |
TBI indicates total body irradiation; PBSC, peripheral blood stem cells; CYA, cyclosporine; MTX, methotrexate.
CYA+, CYA plus other agent(s) except MTX; MTX+, MTX plus other agent(s) except CYA or FK506; FK506+, FK506 plus other agent(s).
HLA-matching criteria used were those accepted at every institution at the time patients underwent transplantation.